Sarconeos

Drug Profile

Sarconeos

Alternative Names: BIO-101

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biophytis
  • Class Obesity therapies
  • Mechanism of Action Proto-oncogene protein c-mas-1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Muscular atrophy
  • Preclinical Duchenne muscular dystrophy; Obesity

Most Recent Events

  • 25 Sep 2017 Biophytis files an IND application with the US FDA for the phase IIb SARA-INT trial in Sarcopenia
  • 25 Sep 2017 Biophytis plans to submit regulatory application to initiate the phase IIb SARA-INT trial for sarcopenic obesity in Belgium, France and Italy, in second half of 2017
  • 25 Sep 2017 Biophytis plans the phase IIb SARA-INT trial for sarcopenic obesity in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top